CD86 and neoplasm: The activation of tumor-associated macrophages was evaluated, in which the M1-phenotype polarized macrophage (F4/80+CD86+CD206−) percentage increased from 20.40% in the control group to 84.00% in the NZCB + US group (Fig. 6g; Additional file 1: Fig. S32).